Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: April 9, 2025
Microarray Patch (General)

MAP, Microneedle Patch

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): PATH, Micron, Queen's University Belfast, ViiV Healthcare, Population Council, LTS Lohmann Therapie-Systeme AG, FHI 360, Georgia Tech, University of Michigan, Istanbul University, Indian Institute of Technology Bombay, Wuhan University, Tufts University
Active
Last updated: April 9, 2025
IUB PRIMA

Hormonal Intrauterine Ball

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): OCON Medical Ltd.
Active
Last updated: April 9, 2025
Injectable Nanoparticles for Targeted Exogenous Testicular Hyperthermy

Magnetic Testicular Hyperthermy, Near-Infrared Testicular Hyperthermy, Metallic Nanoparticles

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Testicular
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Nantong University
Active
Last updated: April 9, 2025
Injectable LNG in PLA/PLGA Microspheres

LNG Long-Acting Microsphere Injectable (LLMI)

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): FHI 360, Shanghai Institute for Biomedical and Pharmaceutical Technologies
Active
Last updated: April 9, 2025
GSK3α-Inhibiting Compound

BRD0705

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Kent State University, Broad Institute, Manipal Centre for Biotherapeutics Research
Active
Last updated: April 9, 2025
Evestra Prodrug 6-Month Injectable

EC625

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Evestra, Inc.
Active
Last updated: April 9, 2025
EluRyng®

ENG + EE Vaginal Ring

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Short-Acting
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): Amneal
Active
Last updated: April 8, 2025
Consap
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Pericoital
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): Central Drug Research Institute, India, HLL Lifecare Limited
Active
Last updated: April 2, 2025
6-Month Microneedle Array Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Massachusetts Institute of Technology